Tsu-Man Chiu

Dr. Tsu-Man Chiu

Department of Dermatology, Changhua Christian Hospital, Changhua, Taiwan
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
Tsu-Man ChiuTsu-Man Chiu
Tsu-Man Chiu
SCSung-Yu Chu
Sung-Yu Chu
At present, iodinated contrast media (ICM) are mostly non-ionic, have low osmolality, and are safe. Even if adverse drug reactions (ADRs) occur, most are chemo-toxic symptoms and require only observation or H1 antihistamines. However, rare, unpredictable, and even life-threatening hypersensitivity can still occur. The aim of this review is to summarize the issues that all relevant staff need to know about and be able to respond to. The most significant risk factor for ICM hypersensitivity is a history of ICM hypersensitivity. For high-risk populations, we must cautiously weigh the advantages and disadvantages of premedication and be aware that breakthrough reactions may still occur. The best policy for patients with a history of severe ICM hypersensitivity is to avoid the same ICM. If ICM are inevitable, skin tests, in vitro tests, and drug provocation tests may help to find a feasible alternative that is safer. The severity of the hypersensitivity is correlated with the positivity rate of these tests, so there is no need for further investigations for patients with only mild reactions. We should also keep in mind that even excipients in ICM may induce hypersensitivity. Detailed, standardized documentation is essential for correct diagnosis and the prevention of future occurrence.

3 January 2025 in Cancers
Verified
Journal Article
Open access
PDF file
Tsu-Man ChiuTsu-Man Chiu
Tsu-Man Chiu
YLYun-Chang Li
Yun-Chang Li
ICI-Chun Chi
I-Chun Chi
MTMing-Hseng Tseng
Ming-Hseng Tseng
Background: Skin cancer is the most common cancer worldwide, with melanoma being the deadliest type, though it accounts for less than 5% of cases. Traditional skin cancer detection methods are effective but are often costly and time-consuming. Recent advances in artificial intelligence have improved skin cancer diagnosis by helping dermatologists identify suspicious lesions. Methods: The study used datasets from two ethnic groups, sourced from the ISIC platform and CSMU Hospital, to develop an AI diagnostic model. Eight pre-trained models, including convolutional neural networks and vision transformers, were fine-tuned. The three best-performing models were combined into an ensemble model, which underwent multiple random experiments to ensure stability. To improve diagnostic accuracy and reduce false negatives, a two-stage classification strategy was employed: a three-class model for initial classification, followed by a binary model for secondary prediction of benign cases. Results: In the ISIC dataset, the false negative rate for malignant lesions was significantly reduced, and the number of malignant cases misclassified as benign dropped from 124 to 45. In the CSMUH dataset, false negatives for malignant cases were completely eliminated, reducing the number of misclassified malignant cases to zero, resulting in a notable improvement in diagnostic precision and a reduction in the false negative rate. Conclusions: Through the proposed method, the study demonstrated clear success in both datasets. First, a three-class AI model can assist doctors in distinguishing between melanoma patients who require urgent treatment, non-melanoma skin cancer patients who can be treated later, and benign cases that do not require intervention. Subsequently, a two-stage classification strategy effectively reduces false negatives in malignant lesions. These findings highlight the potential of AI technology in skin cancer diagnosis, particularly in resource-limited medical settings, where it could become a valuable clinical tool to improve diagnostic accuracy, reduce skin cancer mortality, and reduce healthcare costs.

22 April 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Tsu-Man ChiuTsu-Man Chiu
Tsu-Man Chiu
PHPing-Chun Hsu
Ping-Chun Hsu
MKMohd Yaqub Khan
Mohd Yaqub Khan
CLCheng-An J. Lin
Cheng-An J. Lin
CLChun-Hung Lee
Chun-Hung Lee
AHand Nobutaka Hanagata
and Nobutaka Hanagata
Warts are a common skin problem and are caused by infection with a virus. Warts are currently mainly treated by therapies involving ablating tissue or interrupting cellular division. However, all these existing treatments are either invasive or cause skin pain and tissue destruction. Imiquimod is a synthetic compound that belongs to the imidazoquinolinone family. It has been successfully used as a topical drug to treat external anogenital warts. However, topical imiquimod cream for warts is restricted by low skin permeability, and several side effects such as itching, pain, and erosions occur most frequently following topical treatment. Microneedle technology, a minimally invasive drug delivery system, has the potential to overcome the barrier of the stratum corneum. This technique would also offer a painless treatment choice and provide personalized therapies. In the study, we loaded imiquimod within dissolving microneedles using the molding method. Gelatin was used as a structural material for microneedle formation without adding a crosslinker. To our knowledge, this is the first study of using dissolving microneedles and exploring their utilization with imiquimod for the treatment of warts. First, we added fluorescent dye and trypan blue into the microneedles to evaluate the status of drugs in the microneedles and the degradation property of microneedles made of gelatin, respectively. Here we also prove the strength of the imiquimod microneedles and study their capability to penetrate the skin. The results show no apparent differences in mechanical failure after an additional imiquimod-loaded. Besides, we provide evidence that imiquimod microneedles induce secreted embryonic alkaline phosphatase (SEAP) in the RAW 264.7 macrophages. Gelatin does not affect the imiquimod in microneedles; a similar immune response was affected by the imiquimod alone or imiquimod complexed with gelatin. Our research demonstrates a proof of concept of using imiquimod microneedles for future warts treatment.

29 August 2025 in Bioengineering
Verified
Journal Article
Open access
PDF file
Tsu-Man ChiuTsu-Man Chiu
Tsu-Man Chiu
ICI-Chun Chi
I-Chun Chi
YLYun-Chang Li
Yun-Chang Li
MTMing-Hseng Tseng
Ming-Hseng Tseng
The skin, the largest organ of the body, acts as a protective shield against external stimuli. Skin lesions, which can be the result of inflammation, infection, tumors, or autoimmune conditions, can appear as rashes, spots, lumps, or scales, or remain asymptomatic until they become severe. Conventional diagnostic approaches such as visual inspection and palpation often lack accuracy. Artificial intelligence (AI) improves diagnostic precision by analyzing large volumes of skin images to detect subtle patterns that clinicians may not recognize. This study presents a multiclass skin lesion diagnostic model developed using the CSMUH dataset, which focuses on the Eastern population. The dataset was categorized into seven disease classes for model training. A total of 25 pre-trained models, including convolutional neural networks (CNNs) and vision transformers (ViTs), were fine-tuned. The top three models were combined into an ensemble using the hard and soft voting methods. To ensure reliability, the model was tested through five randomized experiments and validated using the holdout technique. The proposed ensemble model, Swin-ViT-EfficientNetB4, achieved the highest test accuracy of 98.5%, demonstrating strong potential for accurate and early skin lesion diagnosis.

22 August 2024 in Journal of the Formosan Medical Association
Verified
Journal Article
Open access
CLChun-Wei Lu
Chun-Wei Lu
CCChun-Bing Chen
Chun-Bing Chen
Tsu-Man ChiuTsu-Man Chiu
Tsu-Man Chiu
CCChih-Chiang Chen
Chih-Chiang Chen
KWKai-Che Wei
Kai-Che Wei
YLYung-Hung Luo
Yung-Hung Luo
The 2023 consensus from the Taiwanese Dermatological Association (TDA) and Taiwan Lung Cancer Society (TLCS) addresses the management of tyrosine kinase inhibitor (TKI)-induced skin toxicities in non-small cell lung cancer (NSCLC). Providing a comprehensive overview, the consensus reflects recent advances in understanding causes and developmental processes of TKI-related skin toxicities. Aimed at guiding clinicians in Taiwan, the consensus integrates new treatment perspectives while incorporating experiences from local dermatology experts. Recommendations underwent a voting process, achieving consensus when 75% or more of experts agreed, leading to their inclusion. Approved by over 90% of participants, the recommended treatment algorithms for major skin toxicities offer valuable insights for clinicians managing TKI-associated effects in NSCLC patients.

25 May 2024 in Archives of Dermatological Research
Verified
Journal Article
Closed access
PDF file
HCHui-Chin Chang
Hui-Chin Chang
Tsu-Man ChiuTsu-Man Chiu
Tsu-Man Chiu
CLChien-Ying Lee
Chien-Ying Lee
SCShiu-Jau Chen
Shiu-Jau Chen
WLWen-Chieh Liao
Wen-Chieh Liao
SGShuo-Yan Gau
Shuo-Yan Gau